STOCK TITAN

Form 4: Annexon (ANNX) insider purchase under Rule 10b5-1

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Annexon (ANNX) filed a Form 4 reporting an insider purchase by a director. On 10/30/2025, the director bought 4,115 shares of common stock at a $3.17 weighted average price, with individual trades executed between $3.15 and $3.20. The transaction was made under a Rule 10b5-1 trading plan adopted on March 17, 2025. Following the trade, the director beneficially owns 46,175 shares, held directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carson William H.

(Last) (First) (Middle)
C/O ANNEXON, INC.
1400 SIERRA POINT PKWY, BLDG C, STE 200

(Street)
BRISBANE CA 94005

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Annexon, Inc. [ ANNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/30/2025 P(1) 4,115 A $3.17(2) 46,175 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025.
2. This transaction was executed in multiple trades in prices ranging from $3.15 o $3.20, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.
/s/ Jennifer Lew, Attorney-in-Fact 10/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Annexon (ANNX) disclose in this Form 4?

A director purchased 4,115 shares of common stock on 10/30/2025 at a $3.17 weighted average price.

Was the Annexon (ANNX) insider trade under a 10b5-1 plan?

Yes. The transactions were made under a Rule 10b5-1 trading plan adopted on March 17, 2025.

What price range did the ANNX trades occur at?

Trades were executed in a range from $3.15 to $3.20, inclusive.

How many Annexon (ANNX) shares does the director own after the trade?

Following the reported transaction, the director beneficially owns 46,175 shares, held directly.

What was the transaction code reported on the Form 4?

The transaction code was P, indicating an open market or private purchase.

What is the issuer name and ticker in this filing?

The issuer is Annexon, Inc. with ticker ANNX.
Annexon, Inc.

NASDAQ:ANNX

ANNX Rankings

ANNX Latest News

ANNX Latest SEC Filings

ANNX Stock Data

995.69M
134.89M
0.42%
100.05%
9.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE